Market Cap | 321.46K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -1.47k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -7.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -46.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -85.00% |
Recommedations | - | Quick Ratio | 0.40 | Shares Outstanding | 803.66M | 52W Low Chg | 33.00% |
Insider Own | 12.83% | ROA | - | Shares Float | - | Beta | -0.24 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00040 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 7,922,963 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 24,841,041 | Change | 33.33% |
Nano Mobile Healthcare, Inc. operates as a mobile health technology company in the United States. The company develops personalized and point-of-care screening using applications based upon chemical sensing methods. It has a strategic partnership with Theranostics Laboratory, a translational research company. The company was formerly known as Vantage mHealthcare, Inc. and changed its name to Nano Mobile Healthcare, Inc. in September 2015. Nano Mobile Healthcare, Inc. was incorporated in 2010 and is based in Boston, Massachusetts. Nano Mobile Healthcare, Inc. operates as a subsidiary of Nanobeak, Inc.